TG Therapeutics Statistics
Share Statistics
TG Therapeutics has 158.75M
shares outstanding. The number of shares has increased by 1.64%
in one year.
| Shares Outstanding | 158.75M |
| Shares Change (YoY) | 1.64% |
| Shares Change (QoQ) | 0.9% |
| Owned by Institutions (%) | 66.76% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 22,258 |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 23.11M, so 14.85% of the outstanding
shares have been sold short.
| Short Interest | 23.11M |
| Short % of Shares Out | 14.85% |
| Short % of Float | 16.4% |
| Short Ratio (days to cover) | 10.51 |
Valuation Ratios
The PE ratio is 187.06 and the forward
PE ratio is 17.27.
TG Therapeutics's PEG ratio is
2.36.
| PE Ratio | 187.06 |
| Forward PE | 17.27 |
| PS Ratio | 13.29 |
| Forward PS | 3.3 |
| PB Ratio | 19.67 |
| P/FCF Ratio | -107.84 |
| PEG Ratio | 2.36 |
Financial Ratio HistoryEnterprise Valuation
TG Therapeutics has an Enterprise Value (EV) of 4.45B.
| EV / Sales | 13.52 |
| EV / EBITDA | 89.13 |
| EV / EBIT | -109.78 |
| EV / FCF | -109.66 |
Financial Position
The company has a current ratio of 6.25,
with a Debt / Equity ratio of 1.14.
| Current Ratio | 6.25 |
| Quick Ratio | 5.03 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 5.08 |
| Debt / FCF | -6.26 |
| Interest Coverage | 1.75 |
Financial Efficiency
Return on Equity is 10.52% and Return on Invested Capital is 7.85%.
| Return on Equity | 10.52% |
| Return on Assets | 4.05% |
| Return on Invested Capital | 7.85% |
| Revenue Per Employee | $934,670.45 |
| Profits Per Employee | $66,428.98 |
| Employee Count | 352 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 0.35 |
Taxes
| Income Tax | 2.21M |
| Effective Tax Rate | 8.64% |
Stock Price Statistics
The stock price has increased by 88.37% in the
last 52 weeks. The beta is 2.21, so TG Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.21 |
| 52-Week Price Change | 88.37% |
| 50-Day Moving Average | 38.74 |
| 200-Day Moving Average | 30.25 |
| Relative Strength Index (RSI) | 36.91 |
| Average Volume (20 Days) | 3,199,843 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of 329M
and earned 23.38M
in profits. Earnings per share was 0.16.
| Revenue | 329M |
| Gross Profit | 290.52M |
| Operating Income | 41.93M |
| Net Income | 23.38M |
| EBITDA | 49.9M |
| EBIT | 49.62M |
| Earnings Per Share (EPS) | 0.16 |
Full Income StatementBalance Sheet
The company has 179.89M in cash and 253.72M in
debt, giving a net cash position of -73.83M.
| Cash & Cash Equivalents | 179.89M |
| Total Debt | 253.72M |
| Net Cash | -73.83M |
| Retained Earnings | -1.53B |
| Total Assets | 656.69M |
| Working Capital | 484.3M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -40.52M
and capital expenditures -45K, giving a free cash flow of -40.56M.
| Operating Cash Flow | -40.52M |
| Capital Expenditures | -45K |
| Free Cash Flow | -40.56M |
| FCF Per Share | -0.28 |
Full Cash Flow StatementMargins
Gross margin is 88.3%, with operating and profit margins of 12.74% and 7.11%.
| Gross Margin | 88.3% |
| Operating Margin | 12.74% |
| Pretax Margin | 7.78% |
| Profit Margin | 7.11% |
| EBITDA Margin | 15.17% |
| EBIT Margin | 12.74% |
| FCF Margin | -12.33% |
